Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPI-guided MSCs in Knee Osteoarthritis
NCT07313020Phase 1Enrolling by invitation
- Sponsor
- Soochow University
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Modality
- Nanoparticles, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TriCellPr-AC07 in knee osteoarthritis (OA) (2 arms), sponsored by Soochow University. Primary endpoint: MPI-Based Joint Cavity Retention Rate of SPIO-labeled hUC-MSCs at Day 7. Started Dec 2025; status: enrolling by invitation.
02
Drugs
TriCellPr-AC07
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07313020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07313020.